Clinical laboratory professionals and clinical research staff are invited to participate in a clinical course, “Achieving Data Quality and Integrity in Clinical Trials Involving High Consequence Pathogens,” co-hosted on July 11-13 by the Food and Drug Administration (FDA) and the University of Texas Medical Branch (UTMB).
The free course will be held at the University of Nebraska Medical Center, in Omaha, NE. Registration is currently open. The course will be provided for both in-person attendees and virtual participants. Participants will receive their respective continuing education units. The course is interactive and will include both didactic and hands-on exercises, which participants find engaging and helpful.
Why attend?
Participants will learn from world-renowned faculty members. They will be trained to utilize best practices for clinical trials during an outbreak involving high-consequence pathogens, and to recognize and prevent potential risks to data quality and integrity. The course will also aim to enhance cultural awareness and diversity involving clinical trials in geographic locations where there is a high incidence of diseases caused by high consequence pathogens.
The FDA and UTMB have partnered with the
National Emerging Special Pathogens Training and Education Center (NETEC) at the University of Nebraska Medical Center, Omaha, NE, where the course will be held in its state-of-the-art training facility.
For information, visit the course website:
https://www.utmb.edu/orncs/regulatory-ops/clinical-course.
